All News
FDA Approves Renflexis as Second Infliximab Biosimilar
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Read Article
The RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Paradoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Read Article
Inconsistent ESR & CRP in Spondylitis Patients
Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.
Read Article
Anti-IL-23 Therapy Effective in Crohn's Disease
Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.
Read Article
The Cost of Not Taking Medicine
The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.
Read Article
FDA Delays Baricitinib Decision
Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application.
Read Article
The RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Read Article
Acute Steroid Use Comes with Risk
Steroids are known for their acute therpeutic wonders and chronic hazards. Hence most practitioners are comfortable using short term, limited dose corticosteroids for a variety of ailments.
Read Article
Celecoxib Plus PPI Preferred in High Risk Patients
When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.
Read Article
Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain
JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.
Read Article
Stroke Risk Highest in the First Year of Lupus
Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year.
Read Article
Osteoporosis Drugs of Uncertain Efficacy with CKD
More research is needed to determine the benefits and harms of osteoporosis medications on bone mineral density (BMD), fracture risk, and safety among patients with chronic kidney disease (CKD). This is important because complications of CKD include weak bones and increased fracture risk.
Read Article
Osteoporosis Screening Indicated Following Non-Vertebral Fractures
The Archives of Osteoporosis have published the results of a cohort study supporting the use of osteoporosis (OP) screening in those sustaining a non-vertebral fracture in patients over age 50 years, independent of sex of level of trauma sustained.
Read Article
Hydroxychloroquine Underperforms in a Cutaneous Lupus Trial
Hydroxychloroquine has become a mainstay in the treatement of patients with systemic lupus erythematosus (SLE) with proven efficacy in managing many domains of lupus, including skin, joint, and other autoimmune features.
Read Article
The RheumNow Week in Review – 7 April 2017
Dr. Jack Cush reviews highlights from this week's meeting at the Cleveland Clinic Foundation - Biologics Summit VII; and of course a few other tweets and journal articles.
Read Article
Biologic Safety Holds Up in RA
An updated systematic literature review has provided reassuring evidence regarding the increasing safety of biologic disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA), European researchers reported.
Read Article
Abatacept Use During Surgery
The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs.
Read Article
Healthy Bones Formed During Adolescence
An article in the Journal of Bone and Mineral Research reports that physical activity during adolescence is an important determinant in bone strength. (Citation source http://buff.ly/2oph6vO)
Read Article
The RheumNow Week in Review – 31 March 2017
Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:
Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.
Read Article